c-Jun N-terminal kinases (JNKs) are a group of mitogenactivated protein kinase family members that are important in regulating cell growth, proliferation, and apoptosis. Activation of the JNK pathway has been implicated in the formation of several human tumors. We have previously demonstrated that a 55-kDa JNK isoform is constitutively activated in 86% of human brain tumors and more recently demonstrated that this isoform is either JNK2␣2 or JNK2␤2. Importantly, we have also found that among the 10 known JNK isoforms, the JNK2 isoforms are unique in their ability to autophosphorylate in vitro and in vivo. This does not require the participation of any upstream kinases and also leads to substrate kinase activity in vitro and in vivo. To clarify the mechanism of JNK2␣2 autoactivation, we have generated a series of chimeric cDNAs joining portions of JNK1␣2, which does not have detectable autophosphorylation activity, with portions of JNK2␣2, which has the strongest autophosphorylation activity. Through in vivo and in vitro kinase assays, we were able to define a domain ranging from amino acids 218 to 226 within JNK2␣2 that is required for its autophosphorylation. Mutation of JNK2␣2 to its counterpart of JNK1␣2 in this region abrogated the autophosphorylation activity and c-Jun substrate kinase activity in vivo and in vitro. Notably, switching of JNK1␣2 to JNK2␣2 at this 9-amino acid site enabled JNK1␣2 to gain the autophosphorylation activity in vivo and in vitro. We also found two other functional sites that participate in JNK2␣2 activity. One site ranging from amino acids 363 to 382 of JNK2␣2 is required for efficient c-Jun binding in vitro, and a site ranging from amino acids 383 to 424 enhances autophosphorylation intensity, although it is not required for triggering the autophosphorylation in vitro. These findings have uncovered the regions required for JNK2␣2 autophosphorylation, and this information could be used as potential targets to block JNK2␣2 activation.
The c-Jun N-terminal kinases (JNK), 1 together with ERK and p38, constitute the mitogen-activated protein kinase family. JNK contains the dual phosphorylation motif Thr-Pro-Tyr, which is phosphorylated by the upstream kinases MKK4 and MKK7 leading to JNK activation. Since the discovery of JNK as a "p54 microtubule-associated protein kinase" in 1990 (1) and the subsequent molecular cloning of JNK cDNAs in 1994 (2, 3) , much has been learned about the role of the JNK pathway in cell, molecular, and developmental biology. At present, at least 10 isoforms created by alternative splicing from the three JNK genes have been cloned (3) . The role of JNK in regulating cellular proliferation, differentiation, and development is explained at least in part by its regulation of AP-1 transcriptional activity (4) . JNK can phosphorylate c-Jun on Ser-63 and Ser-73 (5), which up-regulates transcriptional activity as a result. In addition, JNK phosphorylates other AP-1 proteins, including JunB, JunD, and ATF2 (6) . Interestingly, the JNK pathway is involved in both proapoptotic and antiapoptotic processes (7) , although there is also evidence that JNK activation plays no role in apoptosis (8) .
JNK1 and JNK2 are ubiquitously expressed, whereas JNK3 is mainly expressed in the central nervous system. Although there may be redundancy between JNK1 and JNK2 (4), several studies have described contexts in which JNK1 and JNK2 tend to play different roles. For example, JNK1 was found to preferentially mediate apoptosis (9 -12) , whereas JNK2 tends to contribute more to proliferation (13) . Consistent with its role in proliferation, JNK2-deficient mice were observed to be resistant to induction of skin papillomas, indicating JNK2 may play a more critical role in tumor formation (14) . Results from antisense studies using antisense JNKs also show antisense JNK2 had stronger inhibition than antisense JNK1 on the human T98G glioblastoma cell line and the PC3 prostate cancer cell line (15, 16) .
We have found that 86% of primary glial tumors show activation of a 55-kDa JNK isoform, but not the 46-kDa isoform (17) . A subsequent study from our laboratory demonstrated that this 55-kDa JNK is a member of the JNK2 gene family (18) . Interestingly, we have found that all of the known JNK2 isoforms, but not the JNK1 or JNK3 isoforms, have autophosphorylation activity and constitutive substrate kinase activity in vitro and in vivo in the absence of upstream kinases (18) . These data support the notion that JNK2 may play a more crucial role in tumor formation than JNK1 or JNK3. In the present study, we asked whether there were a specific domain(s) within JNK2 that leads to its constitutive activation. Identifying such a domain(s) will not only reveal a novel mechanism for how JNKs are activated but will also assist in the design of inhibitors that could be used to block the activation of this tumorigenic JNK isoform. medium supplemented with 10% fetal calf serum (heat inactivated at 56°C for 45 min), 2 mM L-glutamine, and 100 units/ml penicillin/ streptomycin/kanamycin at 37°C in humidified air with 5% CO 2 .
Generation of JNK1␣2/JNK2␣2 Chimeric cDNA Constructs and Recombinant Protein Purification-A series of JNK1␣2/JNK2␣2 chimeric constructs was generated by multiple-step overlapping PCRs and expressed as fusion proteins by cloning in-frame with GFP into pEGFP-C1 (Clontech, Palo Alto, CA) or as bacterial fusion proteins with GST by cloning into pET42 (Novagen, Madison, WI) (Fig. 1A) . Sequencing was performed for all constructs to verify that the construct was correctly generated and that the reading frame was maintained. GST fusion proteins were expressed in Escherichia coli and purified using immobilized glutathione beads (Pierce) according to the manufacturer's protocols. Purified proteins were stored at Ϫ70°C. The quality and quantity of proteins were confirmed by SDS-PAGE and Coomassie Blue staining.
In Vitro Kinase Assay-1 g of the GST fusion protein was incubated in 20 l of the kinase buffer (25 mM HEPES (pH 7.4), 25 mM MgCl 2 , 2 mM dithiothreitol, 0.1 mM NaVO 4 , and 25 mM ␤-glycerophosphate) containing 30 M ATP at 30°C for 45 min. For the substrate kinase assay, 1 g of GST-c-Jun was added in the kinase buffer mixture as the substrate. Reactions were terminated by adding protein loading buffer and boiling for 5 min. Reactions results were further analyzed by Western blot using specific anti-phospho-JNK or anti-phospho-c-Jun antibody (Cell Signaling Technology, Beverly, MA).
Cellular Transfection-U87-MG cells cultured in Dulbecco's modified Eagle's medium were transfected with pEGFP-C1-JNK1␣2/JNK2␣2 chimeras using the Effectene reagent (Qiagen, Valencia, CA). After overnight incubation, the growing medium was changed to serum-free Dulbecco's modified Eagle's medium, and the incubation was continued for an additional 24 h. Cells were then lysed with cold PBS/TDS buffer (phosphate-buffered saline with 1% Triton X-100, 0.5% sodium deoxycholate, 0.1% SDS, 1 mM EDTA, 1 mM phenylmethyl sulfonyl fluoride, one complete inhibitor cocktail; Roche Applied Science), and the total cell lysate was harvested, centrifuged, and used immediately or stored at Ϫ80°C.
Western Blotting-Equal amounts of proteins were loaded and run on 4 -20% SDS-PAGE gel and transferred to nitrocellulose membranes. The membranes were blocked with Blotto for 1 h and then incubated with monoclonal anti-phospho-JNK antibody or monoclonal anti-phospho-c-Jun antibody at 4°C overnight. The membranes were then incubated with the corresponding secondary antibody after being washed with TBST (Tris-Buffered saline Tween-20, 20 mM Tris-HCl, pH 7.5, 0.5 M NaCl, 0.1% Tween 20) three times. The signal was detected with the ECL system (Amersham Biosciences).
Immunofluorescence Microscopic Analysis-Immunofluorescence microscopic analysis was carried out as described previously (18) . Briefly, U87-MG cells grown on coverslips were first transfected with pEGFP-JNK1␣2/JNK2␣2 chimeras using the Effectene reagent (Qiagen). After overnight incubation, cells were continuously cultured in serum-free medium for another 24 h. Cells were then fixed by 4% paraformaldehyde/phosphate-buffered saline for 10 min, followed by 0.2% Triton X-100 treatment for 5 min. The cells then were stained with 4Ј,6Ј-diamidino-2-phenylindole for visualization of the nuclei. After washing with phosphate-buffered saline, the coverslips were mounted with antifade reagent (Molecular Probes), and the results were observed with a Nikon immunofluorescence microscope. Cytoplasmic and nuclear green staining indicated successful transient transfection. The cells successfully transfected from five randomly chosen views under lower magnification (ϫ100) were counted. Cells showing stronger nuclear staining than the cytoplasm were defined as nuclear GFP localization-positive. The percentage of positive GFP nuclear localization was defined as: (cells showing positive nuclear GFP localization)/(cells successfully transfected) ϫ 100%.
RESULTS

JNK2␣2 Kinase Subdomains IX-XI Are Required for Its Autophosphorylation-All
JNKs comprise eleven protein kinase subdomains, which are named I-XI (3). We have previously discovered that all of the JNK2 isoforms, namely, JNK2␣1, JNK2␣2, JNK2␤1, and JNK2␤2, possess autophosphorylation activity and substrate kinase activity without the participation of any upstream kinases (18) . JNK2␣2 has the strongest autophosphorylation and substrate kinase activity for c-Jun and ATF2 in vitro and in vivo, whereas JNK1␣2, an isoform that is otherwise structurally similar to JNK2␣2, does not possess any detectable autophosphorylation and substrate kinase activity in vitro and in vivo. The primary protein structures of JNK1␣2 and JNK2␣2 differ at subdomains I, IV, IX, X, and XI (see Fig.  1B ). Domains I and IV are located in the N terminus, which has FIG. 1. Schematic description of JNK1␣2/JNK2␣2 chimeras. A, a series of JNK1␣2/JNK2␣2 chimeras was generated by the overlapping PCR method using primers containing artificially introduced restriction endonuclease cleavage sites. JNK1␣2 and JNK2␣2 sequences are indicated by white bars and black bars, respectively. Shaded boxes indicate the regions where JNK2␣2 protein possesses multiple different amino acid sequences from JNK1␣2. TPY motif required for JNK activation is indicated by the arrow. B, alignment of human JNK1␣2 and JNK2␣2 protein sequences where they show differences. The sequence required for JNK2␣2 autophosphorylation discovered by this study is underlined. been shown to be critical for both catalytic function and ATP binding for all of the JNK isoforms. Thus, we first hypothesized that the more disparate domains IX, X, and XI would be required for the autophosphorylation of JNK2␣2. To test our hypothesis, we first generated four JNK1␣2/JNK2␣2 chimeras, which contained one, two, three, or four consecutive domains different between JNK1␣2 and JNK2␣2 (Fig. 1A , chimeras [1] [2] [3] [4] . GST fusion proteins obtained from the different chimeric constructs were first examined for in vitro kinase activity. Among these four chimeras, only chimera 1, which contained subdomains IX-XI of JNK2␣2, retained autophosphorylation activity in vitro in the absence of any upstream activating kinase ( Fig. 2A) . We then asked whether chimera 1 still retained substrate kinase activity by incubating the different GST chimeras with kinase buffer, ATP, and GST-c-Jun, but in the absence of any other proteins. The results revealed that only chimera 1 possessed the ability to phosphorylate c-Jun (Fig. 2B) . We then extended our analysis of the autophosphorylation activity of different chimeras in vivo. We constructed pEGFP-chimera expression vectors and transfected these into U87-MG cells. U87 cells normally have a rather weak or undetectable phospho-JNK signal even under serum starvation conditions (19, 20) , which has also been confirmed by our present work (Fig. 2C ). This property makes the U87-MG cell line a good model for the study of JNK autophosphorylation to avoid any confusion with endogenously activated JNK. We have previously shown that when JNK2␣2 is transfected into U87-MG cells under serum depletion conditions it undergoes profound FIG. 2. JNK2␣2 kinase subdomains IX-XI are required for its autophosphorylation. A, GST-chimeras 1-4 were purified, and their autophosphorylation in vitro was examined by Western blot using a specific anti-phospho-JNK antibody. B, in vitro autophosphorylation and substrate kinase activities of GST-chimeras 1-4 were examined by Western blot using anti-phospho-JNK or anti-phospho-c-Jun antibodies. C, plasmids constructed by fusing GFP with chimeras 1-4 were transfected into U-87MG cells. The cell lysate was harvested for analysis of autophosphorylation by Western blot using anti-phospho-JNK antibody. Subcellular localizations of different chimeras were also examined, and the percentage of positive GFP nuclear localization was quantitated by immunofluorescence microscopy (D and E). All figures are representative of three different experiments.
autophosphorylation, whereas JNK1␣2 does not under the same conditions (18) . We found that pEGFP-chimera 1 shows profound autophosphorylation under serum starvation as expected, whereas the other three chimeras showed no or very weak autoactivation (Fig. 2C) . We then examined the subcellular localization of these chimeras in U87-MG cells. We have shown previously that when pEGFP-JNK2␣2 is transfected into U87-MG cells it shows a predominantly nuclear localization when autophosphorylated, whereas GFP-JNK1␣2 either remains in the cytoplasm or shows no preferential localization to the nucleus. Similar to JNK2␣2, pEGFP-chimera 1 also showed a profound nuclear localization (Fig. 2, D and E) . To further dissect the requirement of JNK2␣2 kinase subdomains IX-XI for autophosphorylation, we generated another chimera that joined subdomains I-VIII of JNK2␣2 with subdomains IX-XI of JNK1␣2. As expected, this chimera showed neither in vitro nor in vivo autophosphorylation activity (data not shown). Overall, these results indicate that subdomains IX, X, and XI of JNK2␣2 are required for its autophosphorylation in vitro and in vivo.
Amino acids 218 -226 of JNK2␣2 Are Crucial for Its Autophosphorylation-As chimera 1 had profound autophosphorylation activity, whereas chimeras 2-4 did not, we speculated that the region between amino acids 208 -245 is necessary for JNK2␣2 autophosphorylation. Comparison of the amino acid sequences for JNK2␣2, JNK1␣2, and JNK3␣2 at this portion showed that only amino acids 218 -226 (LVKGCVIFQ) are unique to JNK2␣2 (Fig. 3A) . We hypothesized that this is one of the regions crucial for JNK2␣2 autophosphorylation. To test this notion, we generated another chimera largely based on the JNK1␣2 backbone but bearing amino acids 218 -226 from JNK2␣2 (Fig. 1A, chimera 5 ). Because we also found weak autophosphorylation activity of chimera 2 (Fig. 2C) , we generated another JNK1␣2/JNK2␣2 chimera bearing amino acids 245-292 of JNK2␣2 (Fig. 1A, chimera 6) . Two other JNK2␣2/ JNK1␣2 chimeras were also generated that represented the reciprocal of these new chimeras by using the JNK2␣2 backbone replaced with amino acids 218 -226 or 245-292 from JNK1␣2, respectively ( Fig. 1 A, chimeras 6 and 7) . Interestingly, in vitro kinase assays showed that GST-chimera 5, which differs from JNK1␣2 only at amino acids 218 -226, gained autophosphorylation activity in vitro (Fig. 3, B and C) . Surprisingly, it does not possess substrate kinase activity in vitro (Fig.  3C) . However, chimera 6, essentially a JNK1␣2 molecule only bearing amino acids 245-292 from JNK2␣2, did not show any autophosphorylation and substrate kinase activity in vitro (Fig.  3, B and C) . As expected, when amino acids 218 -226 of JNK2␣2 were switched to the JNK1␣2 sequences, as indicated in chimera 7, autophosphorylation and subsequent substrate kinase activity were lost (Fig. 3, B and C) . However, chimera 8, a JNK2␣2 molecule with amino acids 245-292 switched to its counterpart in JNK1␣2, still retained strong autophosphorylation and substrate kinase activity in vitro (Fig. 3, B and C) . We then transfected these new chimeras into U87-MG cells to study their autophosphorylation in vivo. Similar to the results in vitro, chimeras 5 and 8 showed profound autophosphorylation. Chimera 8 actually showed the highest degree of autoactivation and was even stronger than JNK2␣2 (Fig. 3D) . The autoactivation of pEGFP-chimeras 5 and 8 was also supported by their predominant nuclear localization as revealed by immunofluorescence microscopy (Fig. 3, E and F (Fig. 3C) , we hypothesized that there is another portion within the C-terminal of JNK2␣2 that is necessary for efficient substrate binding in vitro. Because chimera 8 with amino acids 245-292 mutated to its JNK1␣2 counterpart showed autophosphorylation and substrate kinase activity, this site was not likely to be involved in the substrate binding for c-Jun. To map the region responsible for c-Jun binding, we then generated another set of chimeras, chimeras 9 -12. All of these retained amino acids 218 -226 of JNK2␣2 and amino acids 245-292 of JNK1␣2, as shown in Fig. 1A . Kinase assays showed that GST-chimeras 9 and 12 possess much stronger autophosphorylation activity than GST-chimeras 10 and 11 (Fig. 4A) . Substrate kinase assays using GST-c-Jun as the substrate also demonstrated that GST-chimeras 9 and 12 had much stronger substrate kinase activity than GST-chimeras 10 and 11 (Fig.  4B) . Because GST-chimeras 9 and 12 share amino acids 218 -226 and 363-424 in common, our data suggested amino acids 363-424 are required for substrate binding as well as enhancing autophosphorylation. We then transfected pEGFP-chimeras 9 -12 into U87-MG cells to study their autophosphorylation in vivo. Surprisingly, all of these showed similar levels of autophosphorylation comparable with JNK2␣2 (Fig. 4C ). Their autophosphorylation is also supported by a high degree of GFP nuclear localization in transfected U87-MG cells (Fig. 4, D and  E) . In summary, these results suggest that the C-terminal tail ranging from amino acids 363 to 424 of JNK2␣2 is responsible for c-Jun binding as well as for enhancing autophosphorylation in vitro.
The Entire Sequence of JNK2␣2 Is Required for Its Efficient Autophosphorylation in Vitro, but Not in Vivo-To determine the relative contribution of each domain to autophosphorylation, we directly compared all of the chimeras that showed autophosphorylation in vitro. Although we have shown that amino acids 218 -226 of JNK2␣2 are required for its autophosphorylation in vitro and in vivo, chimera 5 shows much less autophosphorylation activity than JNK2␣2 in vitro (Fig. 5A) . Furthermore, chimeras 1, 8, 9, and 12 also showed less autophosphorylation than JNK2␣2, although their intensities are greater than chimera 5 (Fig. 5A) . However, to our surprise, we found that all of these chimeras were autophosphorylated at similar levels in vivo (Fig. 5B) . These data indicate that subdomains of JNK2␣2 outside of amino acids 218 -226 contribute collectively to enhancing efficient autophosphorylation in vitro, although these regions outside of 218 -226 are not required for efficient autophosphorylation in the cell.
DISCUSSION
In this study, we have demonstrated for the first time that amino acids 218 -226 of JNK2␣2 (LVKGCVIFQ) are crucial for its autophosphorylation. By comparing the amino acid sequences of JNK1␣2, which does not show any detectable autophosphorylation and substrate kinase activity in vivo and in vitro, with JNK2␣2, which has the strongest autophosphorylation and substrate kinase activity, we generated a series of JNK1␣2/JNK2␣2 chimeras to refine which domain(s) is critical. Through autophosphorylation and substrate kinase assays, we have shown that all chimeras with this cluster of 9 amino acids maintain or gain autophosphorylation in vitro and in vitro, but those chimeras without this domain lose autophosphorylation activity. Chimeras 1, 5, 11, and 12 all show autophosphorylation in vitro and in vivo, demonstrating that subdomains I-VIII of JNK2␣2 are not essential for autophosphorylation. Exchanging JNK1␣2 at this 9-amino acid domain for its counterpart in JNK2␣2 enabled this construct to fully gain autophosphorylation activity in vivo and in vitro.
Furthermore, exchange of JNK2␣2 at this 9-amino acid domain for its counterpart in JNK1␣2 resulted in a chimera that lost autophosphorylation activity in vivo and in vitro (Fig. 3, B-F) . Although the in vitro autophosphorylation activities of all chimeras are not as strong as that of JNK2␣2 (Fig. 5A) , all of their autophosphorylation activities in vivo are similar to or even stronger than that of JNK2␣2 (Fig. 5B) . Notably, all constructs that lack 218 -226 from JNK2␣2 lack any autophosphorylation activity in vitro or in vivo. These results strongly suggest that amino acids 218 -226 of JNK2␣2 are indispensable for its autophosphorylation.
We have previously ranked the autophosphorylation activity among the four JNK2 isoforms in the order JNK2␣2 ϾJNK2␤2 ϾJNK2␣1 ϾJNK2␤1 (18) . It therefore seems that the C-terminal tail ranging from amino acids 363 to 424, which is possessed by both JNK2␣2 and JNK2␤2, might be responsible for increased autophosphorylation. However, chimera 4, which includes amino acids 363-424 of the JNK2 isoforms, did not show any autophosphorylation in vitro and in vivo (Fig. 2, A-F) , indicating this region is not crucial for triggering autophosphorylation but does enhance autophosphorylation when present, as can be seen in a comparison of chimeras 5 and 12 in Fig. 5A . This is further supported by our results from chimeras 10 and 11 (Fig. 4, A and B) , both of which lack amino acids 363-424 of JNK2␣2, showing less autophosphorylation in vitro than chimeras 1, 8, 9, and 12 (Figs. 4, A and B, and 5A) .
Notably, JNK1␣ and JNK3␣ drastically differ from JNK2␣2 at this region (Fig. 3A) . The crystal structure of JNK2 has not yet been determined, but the crystal structure of JNK3 could provide a framework for modeling the structures for this JNK isoform (21) . At this site, the JNK3 structure shows that most of the nonconserved amino acid residues are solvent exposed and located on the protein surface (corresponding to substrate binding). Thus, it is tempting to speculate that this site may be FIG. 4 . Amino acids 363-425 of JNK2␣2 are required for its substrate kinase activity as well as for enhancing autophosphorylation in vitro, but not in vivo. A, comparison of autophosphorylation activities of different GST chimeras (chimeras 9 -12) in vitro by Western blot using anti-phospho-JNK antibody. B, GST chimeras (9 -12) were incubated with GST-c-Jun, separated by SDS-PAGE, and transferred to nitrocellulose membrane. The autophosphorylation of GST chimeras and GST-c-Jun was detected by Western blot using anti-phospho-JNK or anti-phospho-cJun antibodies. C, plasmids constructed by fusing GFP with chimeras 9 -12 were transfected into U-87-MG cells, and the cell lysate was harvested for analysis of autophosphorylation by Western blot using anti-phospho-JNK antibody. Subcellular localizations of different GFP chimeras in U87-MG cells were also examined, and the percentage of positive GFP nuclear localization was quantitated by immunofluorescence microscopy (D and E). All figures are representative of three different experiments. a docking site for JNK2␣2 itself during autophosphorylation.
It has been shown that after activation all mitogen-activated protein kinases subsequently translocate from the cytoplasm to the nucleus. This was first elucidated for ERK2, which was demonstrated to dimerize first before its nuclear translocation (22) . During homodimerization, phosphorylated ERK2s form dimers with other phosphorylated or unphosphorylated ERK2s, and the final ERK2 in the nuclei is predominantly the activated form. This dimerization and translocation mechanism is most likely utilized during JNK2␣2 autophosphorylation as well. We have observed that JNK1␣2, which does not possess autophosphorylation properties, mainly remains in the cytoplasm. For autophosphorylation to occur, JNK2␣2 molecules have to bind each other first. The autoactivation of JNK2␣2 probably follows a "binding first, phosphorylation second" manner. It is during the binding process that the 9-amino acid site may play a key role.
The substrate-binding site in JNKs has been partially clarified. It has been demonstrated that amino acids 208 -230 of JNK2 contain a specificity-determining region responsible for efficient c-Jun binding and phosphorylation, such that JNK2 binds c-Jun ϳ25 times more efficiently than does JNK1 (23) . This site also enables JNK2␣1 or JNK2␣2 to bind to c-Jun at a 2-fold greater intensity than ATF-2. Our present data from chimeras 1, 8, 9, and 12 tend to support these findings (Figs.  2B, 3C, and 4B) . Thus, the cluster of amino acids from 218 to 226 of JNK2␣2 is likely to play a role in c-Jun binding as well as to be a potential binding site for JNK2␣2 itself.
A recent report has indicated that amino acids 162, 164, 326, 329, and 331 of JNK2␣2 are required for efficient c-Jun docking and its subsequent phosphorylation (24) . Interestingly, these amino acids are rather conserved among all JNK isoforms and all of them are identical in our JNK1␣2/JNK2␣2 chimeras, which suggests they do not play a major role during JNK2␣2 autophosphorylation. However, results from the present study indicate that another region of JNK2␣2 ranging from amino acids 363 to 424 contains another domain responsible for c-Jun binding. This is supported by the fact that chimeras 5, 10, and 11, which possess the LVKGCVIFQ sequence required for autophosphorylation, but not amino acids 363-424 of JNK2␣2, show autophosphorylation but much less c-Jun phosphorylation than chimeras 1, 8, 9, and 12 (Figs. 3C, 4B, and 5A).
Interestingly, JNK2␣1 and JNK2␣2 have a similar efficiency in phosphorylating c-Jun when activated, yet JNK2␣2 has a much stronger autophosphorylation activity in vitro than JNK2␣1 (18) . JNK2␣2 differs from JNK2␣1 in that it contains an additional C-terminal tail ranging from amino acids 383 to 424. Taking all these facts into account, we suggest that amino acids 363-382 of JNK2␣2 comprise a region that would facilitate c-Jun binding, whereas amino acids 383-424 enhance the autophosphorylation of JNK2␣ isoforms when they are found.
We observed a decrease in the autophosphorylation activity of JNK1␣2/JNK2␣2 chimeras in vitro versus in vivo. All of the chimeras that are capable of autophosphorylation show variable levels of autophosphorylation and substrate activity in in vitro assays (Fig. 5A) . However, when transfected into cells the autophosphorylation activity of these chimeras is very similar in vivo with the exception of chimera 8 (Fig. 5B) . Several explanations are possible. First, the upstream kinases MKK4 and MKK7 may preferentially phosphorylate these chimeras in cells. The JNK interaction protein (JIP) scaffold protein family members, which interact with mixed lineage kinases, MKK7, and JNKs, may differentially interact with these chimeras as well (25) (26) (27) (28) . Finally, the interaction of these chimeras with JNK phosphatases, such as MKP-7 (29, 30) , may be diminished. The fact that none of the chimeras generated has in vitro autophosphorylation activity comparable with JNK2␣2 indicates that, although subdomains of JNK2␣2 outside of amino acids 218 -226 are not required for its autophosphorylation, these domains may still play an important role for the efficient autophosphorylation of JNK2␣2 in vitro. However, these findings do not alter the basic conclusion that the domains that we have identified are necessary for activity because chimeras lacking these regions (chimeras 2, 3, 4, 6, and 7) fail to show autophosphorylation activity both in vitro and in vivo.
Although JNK1 and JNK3 play an important role in proapoptosis, the function of JNKs, especially JNK2, during oncogenic transformation and tumor formation has been confirmed in several studies (28, 31, 32) . The fact that JNK2␣2 is a constitutively active isoform may have distinct implications for cancer. Our previous study indicated that the active JNK isoform found in gliomas could be either JNK2␣2 or JNK2␤2 (18) . More recently, we have found that gliomas express only JNK2␣2 mRNA and this isoform can promote tumorigenesis in in vitro studies. 2 Understanding the mechanism underlying JNK2␣2 autophosphorylation will provide insights into how to block these constitutively active JNK signals and perhaps lead to novel therapeutics.
